Abstract
Runt-related transcription factor 3 (RUNX3) has recently been reported to be a possible predictor of sensitivity of cancer cells for photodynamic therapy (PDT), a promising therapeutic modality for keloids. In this study, we aimed to elucidate the implications of RUNX3 for keloid pathogenesis and sensitivity to pheophorbide a-based PDT (Pa-PDT). RUNX3 and proliferating cell nuclear antigen (PCNA) expression were examined in 6 normal skin samples and 32 keloid tissue samples by immunohistochemistry. We found that RUNX3 expression was detected more often in keloid tissues than in dermis of normal skin. In keloid tissues, RUNX3 expression was significantly increased in patients presenting with symptoms of pain or pruritus, and was also significantly related to PCNA expression. The therapeutic effect of Pa-PDT was comparatively investigated in keloid fibroblasts (KFs) with and without RUNX3 expression. Significant differences were found after Pa-PDT between KFs with and without RUNX3 expression in cell viability, proliferative ability, type I collagen expression, generation of reactive oxygen species (ROS), and apoptotic cell death. In addition, RUNX3 expression was significantly decreased after Pa-PDT in KFs, and KFs with downregulation of RUNX3 showed significantly increased cell viability after Pa-PDT. Pa-PDT may be a potential therapeutic modality for keloids, and RUNX3, as a possible contributor to keloid pathogenesis, may improve sensitivity to Pa-PDT in KFs.
| Original language | English |
|---|---|
| Pages (from-to) | 67-75 |
| Number of pages | 9 |
| Journal | Lasers in Medical Science |
| Volume | 30 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Dermatology
Cite this
}
RUNX3 expression is associated with sensitivity to pheophorbide a-based photodynamic therapy in keloids. / Zheng, Zhenlong; Zhu, Lianhua; Zhang, Xianglan; Li, Lianhua; Moon, Sook; Roh, MiRyung; Jin, Zhehu.
In: Lasers in Medical Science, Vol. 30, No. 1, 01.01.2014, p. 67-75.Research output: Contribution to journal › Article
TY - JOUR
T1 - RUNX3 expression is associated with sensitivity to pheophorbide a-based photodynamic therapy in keloids
AU - Zheng, Zhenlong
AU - Zhu, Lianhua
AU - Zhang, Xianglan
AU - Li, Lianhua
AU - Moon, Sook
AU - Roh, MiRyung
AU - Jin, Zhehu
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Runt-related transcription factor 3 (RUNX3) has recently been reported to be a possible predictor of sensitivity of cancer cells for photodynamic therapy (PDT), a promising therapeutic modality for keloids. In this study, we aimed to elucidate the implications of RUNX3 for keloid pathogenesis and sensitivity to pheophorbide a-based PDT (Pa-PDT). RUNX3 and proliferating cell nuclear antigen (PCNA) expression were examined in 6 normal skin samples and 32 keloid tissue samples by immunohistochemistry. We found that RUNX3 expression was detected more often in keloid tissues than in dermis of normal skin. In keloid tissues, RUNX3 expression was significantly increased in patients presenting with symptoms of pain or pruritus, and was also significantly related to PCNA expression. The therapeutic effect of Pa-PDT was comparatively investigated in keloid fibroblasts (KFs) with and without RUNX3 expression. Significant differences were found after Pa-PDT between KFs with and without RUNX3 expression in cell viability, proliferative ability, type I collagen expression, generation of reactive oxygen species (ROS), and apoptotic cell death. In addition, RUNX3 expression was significantly decreased after Pa-PDT in KFs, and KFs with downregulation of RUNX3 showed significantly increased cell viability after Pa-PDT. Pa-PDT may be a potential therapeutic modality for keloids, and RUNX3, as a possible contributor to keloid pathogenesis, may improve sensitivity to Pa-PDT in KFs.
AB - Runt-related transcription factor 3 (RUNX3) has recently been reported to be a possible predictor of sensitivity of cancer cells for photodynamic therapy (PDT), a promising therapeutic modality for keloids. In this study, we aimed to elucidate the implications of RUNX3 for keloid pathogenesis and sensitivity to pheophorbide a-based PDT (Pa-PDT). RUNX3 and proliferating cell nuclear antigen (PCNA) expression were examined in 6 normal skin samples and 32 keloid tissue samples by immunohistochemistry. We found that RUNX3 expression was detected more often in keloid tissues than in dermis of normal skin. In keloid tissues, RUNX3 expression was significantly increased in patients presenting with symptoms of pain or pruritus, and was also significantly related to PCNA expression. The therapeutic effect of Pa-PDT was comparatively investigated in keloid fibroblasts (KFs) with and without RUNX3 expression. Significant differences were found after Pa-PDT between KFs with and without RUNX3 expression in cell viability, proliferative ability, type I collagen expression, generation of reactive oxygen species (ROS), and apoptotic cell death. In addition, RUNX3 expression was significantly decreased after Pa-PDT in KFs, and KFs with downregulation of RUNX3 showed significantly increased cell viability after Pa-PDT. Pa-PDT may be a potential therapeutic modality for keloids, and RUNX3, as a possible contributor to keloid pathogenesis, may improve sensitivity to Pa-PDT in KFs.
UR - http://www.scopus.com/inward/record.url?scp=84939881438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939881438&partnerID=8YFLogxK
U2 - 10.1007/s10103-014-1614-4
DO - 10.1007/s10103-014-1614-4
M3 - Article
C2 - 24957188
AN - SCOPUS:84939881438
VL - 30
SP - 67
EP - 75
JO - Lasers in Medical Science
JF - Lasers in Medical Science
SN - 0268-8921
IS - 1
ER -